No Data
No Data
Piper Sandler Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Maintains Target Price $40
Bonum Therapeutics Appoints Samuel C. Blackman, MD, PhD, to Its Board of Directors
Why Is Day One Biopharmaceuticals Inc. (DAWN) Among the Best Up and Coming Stocks to Buy According to Analysts?
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
Day One Biopharmaceuticals Announces Leadership Transition
Express News | Day One Announces Retirement of DR. Samuel Blackman, Co-Founder and Head of Research & Development